The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | An insight into sequencing bispecifics and CAR-T in multiple myeloma
In this video, Peter Forsberg, MD, Colorado Blood Cancer Institute, Denver, CO, shares his view on the current approach to sequencing bispecific antibodies and CAR T-cell therapy in multiple myeloma (MM), emphasizing the importance of treating patients with a T-cell–based therapy as soon as possible. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
